Complete immobility produced in dogs by xylazine-atropine: antagonism by 4-aminopyridine and yohimbine.
D015761:4-Aminopyridine; D000631:Aminopyridines / Q000494:pharmacology*; D000818:Animals; D001143:Arousal / Q000187:drug effects; D001285:Atropine / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D002317:Cardiovascular Agents / Q000494:pharmacology*; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D004285:Dogs / Q000502:physiology*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D008297:Male; D012018:Reflex / Q000187:drug effects; D012119:Respiration / Q000187:drug effects; D013843:Thiazines / Q000037:antagonists & inhibitors*; D014991:Xylazine / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D015016:Yohimbine / Q000494:pharmacology*
D000631:Aminopyridines; D002317:Cardiovascular Agents; D000697:Central Nervous System Stimulants; D013843:Thiazines; D014991:Xylazine; D015016:Yohimbine; D001285:Atropine; D015761:4-Aminopyridine